<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226937</url>
  </required_header>
  <id_info>
    <org_study_id>DIRECT</org_study_id>
    <nct_id>NCT04226937</nct_id>
  </id_info>
  <brief_title>DLBCL Interim Response Evaluation for Customised Therapy</brief_title>
  <acronym>DIRECT</acronym>
  <official_title>DLBCL Interim Response Evaluation for Customised Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK Cambridge Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with&#xD;
      high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic&#xD;
      subtype and an integrated response evaluation determined early in first-line therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be done by integrating data and samples collected from patients undergoing standard&#xD;
      of care treatment for high-grade B cell lymphoma&#xD;
&#xD;
      Data will be integrated from&#xD;
&#xD;
        1. Clinical risk factors from the International Prognostic Index (IPI)&#xD;
&#xD;
        2. Up-front genomic subtype based on molecular profiling of diagnostic biopsy&#xD;
&#xD;
        3. Serial ctDNA monitoring during treatment.&#xD;
&#xD;
        4. Radiological response imaging&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish a robust molecular monitoring pipeline.</measure>
    <time_frame>3-5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful identification of trackable mutations in collected samples. Feasibility will be met if more than 75% of the samples yield trackable mutations across the whole study.</measure>
    <time_frame>3-5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the utility of serial ctDNA assessment as a predicator of clinical outcome in high-grade B cell lymphoma.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the utility of integrated data from clinical risk factors (IPI), up-front genotype, serial ctDNA response and radiological assessment (CT or PET-CT).</measure>
    <time_frame>3-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>When the pipeline is optimised can these 4 parameters be available within 6 weeks, i.e. by completion of Cycle 2.</measure>
    <time_frame>3-5 years</time_frame>
    <description>Clinical risk factors from the International Prognostic Index (IPI)&#xD;
Up-front genomic subtype based on molecular profiling of diagnostic biopsy&#xD;
Serial ctDNA monitoring during treatment.&#xD;
Radiological response imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Identification of the de novo somatic variants in high-grade B cell lymphoma from collected ctDNA and tissue samples.</measure>
    <time_frame>3-5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assess the utility of ctDNA to track clonal evolution in patients undergoing treatment for high-grade B cell lymphoma.</measure>
    <time_frame>3-5 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>High-grade B-cell Lymphoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not Applicable as this is a translational, sample collection study.</intervention_name>
    <description>Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.&#xD;
Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.&#xD;
Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      ctDNA and Biopsy Tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diffuse Large B Cell Lymphoma (DLBCL) or closely related high-grade B cell&#xD;
        lymphomas including, but not limited to:&#xD;
&#xD;
          -  DLBCL NOS&#xD;
&#xD;
          -  Transformed follicular lymphoma&#xD;
&#xD;
          -  High grade B cell lymphoma with rearrangement of BCL2/BCL6 and MYC&#xD;
&#xD;
          -  Plasmablastic lymphoma&#xD;
&#xD;
          -  Primary Mediastinal Large Cell lymphoma&#xD;
&#xD;
          -  Burkitt lymphoma&#xD;
&#xD;
          -  Primary Central Nervous System lymphoma&#xD;
&#xD;
          -  High grade B cell lymphoma NOS&#xD;
&#xD;
        Undergoing Standard of Care treatment for their lymphoma.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Have given written informed consent to participate.&#xD;
&#xD;
          -  Age â‰¥ 18 years at the time of consent.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of previously untreated high-grade B cell lymphoma.&#xD;
&#xD;
          -  Planned to receive immunochemotherapy as first-line therapy, e.g. R-CHOP therapy.&#xD;
&#xD;
          -  Planned or completed standard of care imaging (CT or PET-CT)&#xD;
&#xD;
          -  Able to give blood.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to receive immunochemotherapy as first-line therapy due to co-morbidity or&#xD;
             personal choice.&#xD;
&#xD;
          -  Patients who have already started high dose steroids as a treatment for their&#xD;
             lymphoma.&#xD;
&#xD;
          -  Known diagnosis of infectious blood-borne virus e.g. Hep B, Hep C or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Hodson, PhD MRCP FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phil Barry, PhD</last_name>
    <phone>+44(0)122325634</phone>
    <email>philip.barry@addenbrookes.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Barry, PhD</last_name>
      <email>philip.barry@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Daniel Hodson, PhD MRCP FRCPath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Daniel Hodson</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

